Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
64Cu-DOTATATE PET/CT for NETs
NCT03673943Phase 3Completed
- Sponsor
- RadioMedix
- Start
- Aug 2018
- Primary completion
- Mar 2019
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
A Phase 3 trial of copper Cu 64 dotatate in neuroendocrine tumors (NETs), sponsored by RadioMedix. Started Aug 2018; status: completed.
02
Drugs
copper Cu 64 dotatate
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT03673943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03673943.